Yu Yanagisawa received his PhD in Chemical and Biomolecular Engineering, Graduate School of Engineering, The University of Tokyo. During his studies, he conducted research on functional polymer materials in Takuzo Aida’s laboratory. He joined CellFiber in February 2018, became a director in May of the same year, and assumed the position of representative director in June 2019. Immediately after joining the company, he has been serving as a principal investigator in projects sponsored by AMED, NEDO, etc., and has been leading the business of CellFiber.
Aki Adachi received her master’s degree from Graduate School of Arts and Sciences, the University of Tokyo (Shoji Takeuchi Laboratory, Institute of Industrial Science). After working for a private company for several years, she was appointed as the research promoter of the JST ERATO Takeuchi Bio Integration Project. In April 2015, together with Takeuchi, Okitsu, and Onoe, she established CellFiber Co., Ltd. based on the cell fiber technology that was the result of the ERATO project, and became the representative director. Currently, she is responsible for the development of internal and external business infrastructure and serves as the representative with Yanagisawa.
After receiving a PhD in regenerative medicine from Tottori University (Japan), he engaged in research at Tottori University, San Raffaele Scientific Institute (Italy), University College London, and Queen Mary University of London (UK). Since 2015, as the manager for the Asian and Oceanian territory, he developed, refined, and implemented the strategy of the Cell and Gene Therapy Catapult, an organization established by the UK government for the industrialization of regenerative medicine, including gene and cell therapy. In November 2019, he became an independent consultant for Start-up, Non-profit, and Large pharmaceutical companies in Europe and Asia such as France, the UK, and Japan. In December 2020, he was appointed to the board of CellFiber. He is also the Division Chairman of Advanced Manufacturing Technology, Gene & Cell Therapy at the Manufacturing Technology Association of Biologics. He has over 18 years of experience in regenerative medicine, cell and gene therapy field.
Hiroaki Onoe received his PhD in Information Science and Engineering from the University of Tokyo, and had been an assistant professor in Shoji Takeuchi’s lab since April 2009, where he developed cell fiber technology as an assistant researcher and group leader of the ERATO Takeuchi Project. He started his career as an independent PI in the Faculty of Science and Technology at Keio University in April 2014, and has also served as a Board Director of CellFiber since April 2016. In April 2017 he was awarded the Young Scientist Prize of the Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology for his research on in vitro tissue formation including cell fibers.
Kuni. Suzuki has been dedicating his last circa. 20 years in the space of cell & gene therapies/regenerative medicine as the management of MEDINET Co., Ltd as CEO, CBO and so on, after his business career starting at ESSO SEKIYU K.K., an affiliate of Exxon Corp, and working at Nikko Securities Co., Ltd. in the area of investment banking, commercial banking and custodian banking over 20 years.
With joining to MEDINET in 2006, he also play an important functions at FIRM (Forum for Innovative Regenerative Medicine), the industrial advocacy for CGT/RM in Japan by working together with ARM, ISCT, CCRM, C&G Catapult and others.
Professor ,The University of Tokyo
Specially-appointed professor, The University of Tokyo